Published in Pediatr Blood Cancer on November 18, 2011
PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell Int (2015) 1.42
Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206. Biomed Res Int (2014) 1.41
Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal (2013) 1.17
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res (2014) 0.94
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer (2014) 0.90
New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol (2012) 0.89
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res (2015) 0.88
Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med Genomics (2014) 0.88
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer (2014) 0.87
A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study. Pediatr Blood Cancer (2014) 0.86
Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer (2012) 0.85
Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma (2013) 0.81
Too much AKT turns PAX3-FKHR dead: a prospect of novel therapeutic strategy for alveolar rhabdomyosarcoma. Oncotarget (2012) 0.80
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther (2015) 0.79
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76
Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep (2017) 0.75
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci (2001) 6.66
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74
PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis (2004) 4.33
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell (2002) 3.53
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther (2005) 2.23
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res (2005) 2.09
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
Guidelines for accurate EC50/IC50 estimation. Pharm Stat (2012) 1.95
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res (2002) 1.84
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res (2007) 1.76
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol (2006) 1.70
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res (2002) 1.64
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma (2005) 1.22
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J (2002) 1.16
Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res (2005) 1.14
Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res (2006) 1.07
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.00
Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis (2005) 0.96
Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells. Endocrinology (2005) 0.89
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53
Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res (2008) 4.22
Copy number variation at 1q21.1 associated with neuroblastoma. Nature (2009) 4.10
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35
Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol (2012) 2.32
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res (2009) 2.02
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med (2011) 1.96
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93
Deep neuromuscular blockade during spinal surgery reduces intra-operative blood loss: A randomised clinical trial. Eur J Anaesthesiol (2020) 1.92
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene (2005) 1.86
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol (2002) 1.82
Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol (2006) 1.81
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet (2012) 1.74
Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (2005) 1.74
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol (2007) 1.73
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One (2007) 1.72
ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell (2012) 1.71
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res (2007) 1.71